Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Genetics and Vaccine Development for SARS-CoV2 in the Era of Personalized Medicine

Author(s): Eirini Konstantina Tafanidou and Despoina Gkentzi*

Volume 22, Issue 1, 2022

Published on: 20 July, 2021

Article ID: e200721194929 Pages: 3

DOI: 10.2174/1871526521666210720124950

conference banner
Abstract

Since the emergence of SARS-CoV-2 in late December 2019, scientists have been racing against time to effectively develop a vaccine. As the techniques of personalized medicine are becoming more understood and approachable for mankind, vaccinations using such technologies could advance the treatment of all patients taking into consideration their genetic and biochemical background. As such, we anticipate that patients will be treated more effectively and potentially have fewer symptoms and side effects. This perspective aims to raise awareness of the oncoming novel treatment of diseases, especially during the coronavirus pandemic.

Keywords: SARS-CoV-2, vaccines, personalized medicine, genetics, pandemic, immune response.

[1]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation, and treatment of coronavirus (COVID-19).In: StatPearls Treasure island. Statpearls publishing 2021.
[2]
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[3]
Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020; (20): 30082-7.
[http://dx.doi.org/10.1016/j.jmii.2020.03.022] [PMID: 32265180]
[4]
Fani M, Teimoori A, Ghafari S. Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections. Future Virol 2020; 15(5): 317-23.
[http://dx.doi.org/10.2217/fvl-2020-0050]
[5]
Yi Y, Lagniton PNP, Ye S, Li E, Xu R-H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020; 16(10): 1753-66.
[http://dx.doi.org/10.7150/ijbs.45134] [PMID: 32226295]
[6]
Konno Y, Kimura I, Uriu K, et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep 2020; 32(12)108185
[http://dx.doi.org/10.1016/j.celrep.2020.108185] [PMID: 32941788]
[7]
Mohammad S, Bouchama A, Mohammad Alharbi B, et al. SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic divergence and functional convergence. Pathogens 2020; 9(9): 677.
[http://dx.doi.org/10.3390/pathogens9090677] [PMID: 32825438]
[8]
Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1): 1-9.
[http://dx.doi.org/10.12932/AP-200220-0772] [PMID: 32105090]
[9]
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75(7): 1564-81.
[http://dx.doi.org/10.1111/all.14364] [PMID: 32396996]
[10]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[11]
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020; 11: 1441.
[http://dx.doi.org/10.3389/fimmu.2020.01441] [PMID: 32612615]
[12]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[13]
Ghahramani S, Tabrizi R, Lankarani KB, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res 2020; 25(1): 30.
[http://dx.doi.org/10.1186/s40001-020-00432-3] [PMID: 32746929]
[14]
Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2: 1-8.
[http://dx.doi.org/10.1007/s42399-020-00363-4] [PMID: 32838147]
[15]
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.017] [PMID: 32173574]
[16]
Godri Pollitt KJ, Peccia J, Ko AI, et al. COVID-19 vulnerability: The potential impact of genetic susceptibility and airborne transmission. Hum Genomics 2020; 14(1): 17.
[http://dx.doi.org/10.1186/s40246-020-00267-3] [PMID: 32398162]
[17]
Bwire GM. Coronavirus: Why men are more vulnerable to Covid-19 than women? SN Compr Clin Med 2020; 2: 1-3.
[http://dx.doi.org/10.1007/s42399-020-00341-w] [PMID: 32838138]
[18]
Iwasaki A, Mazure CM. The coronavirus affects women and men differently - learning how may help stop the pandemic 2020. Available from: https://medicine.yale.edu/news-article/25385/
[19]
Cunningham A. COVID-19 kills more men than women. The immune system may be why 2020. Available from: https://www.sciencenews. org/article/coronavirus-covid-19-kills-more-men-than-women-why-immune-system
[20]
Gagliardi MC, Tieri P, Ortona E, Ruggieri A. ACE2 expression and sex disparity in COVID-19. Cell Death Discov 2020; 6: 37.
[http://dx.doi.org/10.1038/s41420-020-0276-1] [PMID: 32499922]
[21]
Li Y, Jerkic M, Slutsky AS, Zhang H. Molecular mechanisms of sex bias differences in COVID-19 mortality. Crit Care 2020; 24(1): 405.
[http://dx.doi.org/10.1186/s13054-020-03118-8] [PMID: 32646459]
[22]
Hon KLE, Leung KKY. Pediatric COVID-19: what disease is this? World J Pediatr 2020; 16(4): 323-5.
[http://dx.doi.org/10.1007/s12519-020-00375-z] [PMID: 32556887]
[23]
Bhopal S, Bagaria J, Bhopal R. Children’s mortality from COVID-19 compared with all-deaths and other relevant causes of death: Epidemiological information for decision-making by parents, teachers, clinicians and policymakers. Public Health 2020; 185: 19-20.
[http://dx.doi.org/10.1016/j.puhe.2020.05.047] [PMID: 32516623]
[24]
DeBiasi RL, Song X, Delaney M, et al. Severe coronavirus disease-2019 in children and young adults in the washington, dc, metropolitan region. J Pediatr 2020; 223: 199-203.e1.
[http://dx.doi.org/10.1016/j.jpeds.2020.05.007] [PMID: 32405091]
[25]
Erener S. Diabetes, infection risk and COVID-19. Mol Metab 2020; 39101044
[http://dx.doi.org/10.1016/j.molmet.2020.101044] [PMID: 32585364]
[26]
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: Understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8(9): 782-92.
[http://dx.doi.org/10.1016/S2213-8587(20)30238-2] [PMID: 32687793]
[27]
Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res 2020; 288198114
[http://dx.doi.org/10.1016/j.virusres.2020.198114] [PMID: 32800805]
[28]
Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: Principles, progress and prospects. Vaccine 1999; 18(9-10): 765-77.
[http://dx.doi.org/10.1016/S0264-410X(99)00271-6] [PMID: 10580187]
[29]
Schmit C. The vaccine quest. Sci Am 2020; 322(6): 40-3.
[http://dx.doi.org/10.1038/scientificamerican0620-40]
[30]
Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020; 19(5): 305-6.
[http://dx.doi.org/10.1038/d41573-020-00073-5] [PMID: 32273591]
[31]
Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev 2020; 35: 43-9.
[http://dx.doi.org/10.1016/j.prrv.2020.06.010] [PMID: 32653463]
[32]
Castiblanco J, Anaya JM. Genetics and vaccines in the era of personalized medicine. Curr Genomics 2015; 16(1): 47-59.
[http://dx.doi.org/10.2174/1389202916666141223220551] [PMID: 25937813]
[33]
Vandenberghe LH. COVID-19: Gene transfer to the rescue? Hum Gene Ther 2020; 31(11-12): 605-7.
[http://dx.doi.org/10.1089/hum.2020.29125.lhv] [PMID: 32469280]
[34]
American Physiological Society.; Individualized treatment for COVID-19 patients should be based on three disease phases 2020.Available from:. https://medicalxpress.com/news/2020-06-individualized-treatment-covid-patients-based.html
[35]
Crisci CD, Ardusso LRF, Mossuz A, Müller L. A precision medicine approach to sars-cov-2 pandemic management. Curr Treat Options Allergy 2020; 7: 1-19.
[http://dx.doi.org/10.1007/s40521-020-00258-8] [PMID: 32391242]

Rights & Permissions Print Cite
Article Metrics
14
1
© 2024 Bentham Science Publishers | Privacy Policy